DGKα inhibitors have previously been considered for development as anti-cancer therapy, not only for their effect on the cancer but also on the T-cell anti-cancer immune response (Arranz-Nicolás and Mérida, 2020; Sakane et al., 2008, 2016). Here, DGKA is linked to cancer.